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Chronic pain is highly debilitating and impacts 
greatly upon the patients’ wellbeing and quality of life. 
Chronic pain arises due to disease or treatment that cause 
dysfunction to the sensory nervous system, including 
arthritis, diabetes and chemotherapy induced sensory 
neuropathy. In diabetic patients, for example, sensory 
neurons in the peripheral and central (spinal cord) 
nervous system become hyperactive. This is replicated 
in rodent models of neuropathic pain, with C fibre and A 
fibre nociceptors responding with an increase in neuronal 
evoked and ongoing activity [1] as well as the onset of 
central sensitisation in the spinal cord. However, effective 
treatment for chronic pain is still a huge unmet clinical 
need.
Development of neuropathic pain is modulated by 
changes in expression and/or activity of voltage gated 
ion channels, neuropeptides and growth factors (such as 
upregulation of nerve growth factor in cancer and arthritic 
pain), which can influence sensory neuron excitability as 
well as altered structural components (sensory nerve fibre 
aberrant growth or degeneration) of the sensory neuron. 
Recent evidence now presents a prominent role for the 
angiogenic growth factor; vascular endothelial growth 
factor-A (VEGF-A) to impact upon the sensory nervous 
system, with nociceptive and neuroprotective roles 
acknowledged [2, 3] . 
VEGF-A is widely recognised to regulate blood 
vessel function and integrity. However, alterations in 
VEGF-A expression and signalling profiles is strongly 
associated with a number of angiogenic related 
pathologies such as diabetes, arthritis and cancer, all of 
which are associated with chronic pain development. 
VEGF-A acts upon the sensory neuron by inducing 
sensory neuron axonal outgrowth and survival [2, 4, 5], 
and in early rodent studies highlighting a role of VEGF-A 
in inflammatory pain. The VEGF-A family consists of a 
number of differing isoform subtypes, with alternative 
splicing of exon 8 giving rise to VEGF-Axxxa (proximal 
splice site selection) and VEGF-Axxxb (exon 8b distal 
splice site selection) [6] . Differing exon content gives 
each of these isoforms distinct signalling and unique 
functional attributes compared to the sister isoforms [2, 
4]. Therefore understanding the balance of these pro and 
anti-nociceptive VEGF-A isoforms and the control of 
exon 8 splice site selection is crucial in the development 
of analgesics. 
The VEGF-A family signal through receptor 
tyrosine kinases VEGF R1 and VEGF R2 in addition 
to neuropilin co-receptors. VEGFR2 is expressed on 
myelinated A fibre and unmyelinated C fibre sensory 
neurons and is activated in rodent models of neuropathic 
pain. Such activity is associated with increased VEGF-
Axxxa and reduced VEGF-Axxxb expression in both the 
peripheral (DRG, skin) [7] and central (spinal cord) [3] 
sensory nervous systems. Administration of VEGFxxxa 
sensitises C fibre mechanically sensitive nociceptors to 
which leads to increased transmission of pain signals and 
development of mechanical allodynia [7]. This is mediated 
by transient receptor potential vanilloid 1 (TRPV1) and 
TRPA1 channel activity. VEGF-A165a potentiates capsaicin 
(TRPV1 agonist) induced DRG sensory neuronal 
responses and TRPV1 phosphorylation. Consequently, 
VEGF-A165a mediated mechanical hyperalgesia was 
completely abolished following ablation of TRPV1 
signalling either through TRPV1 knockout mice or 
pharmacological inhibition [7]. It is important to note that 
the anti-angiogenic VEGF-A165b suppresses TRPV1 and 
TRPA1 mediated activation of DRG sensory neurons, C 
fibre sensitisation and neuropathic pain [7], independent of 
VEGF-A165a induced activity, therefore is anti-nociceptive.
The sensory neurons have the innate ability to 
adapt to stress whereby during disease such as diabetes or 
peripheral nerve trauma, central sensitisation is induced 
in the spinal cord. Intrathecal treatment to target spinal 
cord central sensitisation with VEGF-A165b leads to an 
increase in withdrawal thresholds in naive animals and 
alleviated neuropathic pain [3]. Alternative splicing by 
selecting exonal content produces an extended protein 
family allowing for the expansion of physiological 
function from a single gene. We have identified that 
VEGF-Axxxa expression (exon8a targeted) is dependent 
upon serine arginine protein kinase 1 (SRPK1) - serine 
arginine splice factor (SRSF1) alternative splicing in a 
number of pathologies as well as chronic pain states [3, 7]. 
Inhibition of SRPK1 prevents VEGF-Axxxa expression and 
consequently preferentially leads to increased proportion 
of the anti-nociceptive isoform VEGF-Axxxb, thus chronic 
pain is inhibited [3, 7]. Identifying key alternative splicing 
events allows for fine tuning the design of pain killing 
agents by preventing the formation of pro-nociceptive 
mediators such as VEGF-Axxxa though maintaining other 
essential key isoforms (VEGF-Axxxb).
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Recent investigations outline that the angiogenic 
growth factor, VEGF-A, is integral for the modulation 
of nociception and onset of chronic pain. Understanding 
these signalling events such as alternative splicing, is 
key to providing effective and novel analgesia to prevent 
sensory neuronal damage and chronic pain.
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